Psilocybin With Psychotherapy Shows Sustained Antidepressant Effects In New Study
A new long term study suggests psilocybin paired with structured psychotherapy, helps with treatment resistant depression for up to a year.
Read More
New Brain Scan Study Looks At Psychedelics And Emotional Processing
Brain scans are beginning to show a more detailed picture of how regular psychedelic users may process emotional threat. Single sessions may matter as much as habits, since one dose of psilocybin may leave lasting effects. A recent brain imaging study found that people who regularly use psychedelics outside clinical settings responded differently to emotional […]
Read More
Woman with Alzheimer’s hadn’t spoken in 5 years. Then she took a dose of psilocybin and everything changed
A woman suffering from Alzheimer's started speaking for the first time in five years after a single dose of psilocybin.
Read More
New Psilocybin Study Finds Rapid Depression Relief After One Dose
There's a new Swedish clinical trial that adds to the growing case for psilocybin as a fast acting depression treatment.
Read More
Psychedelic Drug Market Could Reach $14.9 Billion by 2035, Report Says
The forecast reflects a shift in mental health, where ketamine, psilocybin, MDMA, and other compounds are moving from fringe to mainstream.
Read More
A Single Dose of Psilocybin May Leave Lasting Changes in the Brain
The findings add another piece to a central question: how can one guided experience produce changes that seem to outlast the drug itself?
Read More
Could Psilocybin Help People Quit Smoking?
A new Johns Hopkins study suggests that psilocybin, the psychedelic compound in certain mushrooms, may help some people quit smoking.
Read More
How Media Outlets Are Reacting to Trump’s Psychedelics Executive Order
Trump’s executive order on psychedelics pushed a once fringe issue into the center of health policy. The coverage shows a clear pattern.
Read More
What Trump’s Psychedelics Executive Order Means for Psilocybin
The executive order mentions ibogaine, but psilocybin may be the real winner. How priority vouchers, Right to Try, and rescheduling reshape the path to FDA approval.
Read More
Trump Signs Executive Order to Accelerate FDA Review of Psychedelic Therapies
Trump framed the order as a response to the mental health crisis facing American veterans. Psychedelic therapy advocates are watching the move closely.
Read More